Enfortumab vedotin (EV) in combination with pembrolizumab (P) versus chemotherapy in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC): Subgroup analyses results from EV-302, a phase 3 global study

被引：6

作者：

Van Der Heijden, Michiel Simon ^{[1
]}

Powles, Thomas ^{[2
]}

Gupta, Shilpa ^{[3
]}

Bedke, Jens ^{[4
]}

Kikuchi, Eiji ^{[5
]}

De Wit, Ronald ^{[6
]}

Galsky, Matt D. ^{[7
]}

Duran, Ignacio ^{[8
]}

Necchi, Andrea ^{[9
]}

Retz, Margitta ^{[10
]}

Yu, Evan Y. ^{[11
]}

Hoffman-Censits, Jean H. ^{[12
]}

Iyer, Gopa ^{[13
]}

Park, Se Hoon ^{[14
]}

Su, Wen-Pin ^{[15
]}

Parmar, Hema ^{[16
]}

Guan, Xuesong ^{[16
]}

Gorla, Seema Rao ^{[17
]}

Homet Moreno, Blanca ^{[18
]}

Valderrama, Begona Perez ^{[19
]}

机构：

[1] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands

[2] St Bartholomews Hosp London, London, England

[3] Cleveland Clin, Taussig Canc Inst, Cleveland, OH USA

[4] Univ Hosp Tubingen, Tubingen, Germany

[5] St Marianna Univ, Sch Med, Kanagawa, Japan

[6] Erasmus MC, Rotterdam, Netherlands

[7] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Genitourinary Med Oncol, New York, NY USA

[8] Hosp Univ Marques Valdecilla, IDIVAL, Santander, Cantabria, Spain

[9] IRCCS San Raffaele Hosp & Sci Inst, Milan, Italy

[10] Tech Univ Munich, Rechts Isar Univ Hosp, Munich, Germany

[11] Univ Washington, Seattle Canc Care Alliance, Seattle, WA USA

[12] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA

[13] Mem Sloan Kettering Canc Ctr, New York, NY USA

[14] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea

[15] Natl Cheng Kung Univ Hosp, Tainan, Taiwan

[16] Seagen Inc, Bothell, WA USA

[17] Astellas Pharma Inc, Northbrook, IL USA

[18] Merck & Co Inc, Rahway, NJ USA

[19] Hosp Univ Virgen Rocio, Seville, Spain

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期

关键词：

D O I：

10.1200/JCO.2024.42.4_suppl.LBA530

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：LBA530 / LBA530

页数：1